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Abstract
This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used
as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors
can develop and use study results measured by PRO instruments to support claims in approved
product labeling (see appendix point 1). It does not address the use of PRO instruments for
purposes beyond evaluation of claims made about a drug or medical product in its labeling. By
explicitly addressing the review issues identified in this guidance, sponsors can increase the
efficiency of their endpoint discussions with the FDA during the product development process,
streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about
the patient's perspective of treatment benefit at the time of product approval.
A PRO is a measurement of any aspect of a patient's health status that comes directly from the
patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In
clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or
more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the
purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out
activities of daily living), to extremely complex concepts such as quality of life, which is widely
understood to be a multidomain concept with physical, psychological, and social components. Data
generated by a PRO instrument can provide evidence of a treatment benefit from the patient
perspective. For this data to be meaningful, however, there should be evidence that the PRO
instrument effectively measures the particular concept that is studied. Generally, findings measured
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by PRO instruments may be used to support claims in approved product labeling if the claims are
derived from adequate and well-controlled investigations that use PRO instruments that reliably
and validly measure the specific concepts at issue.
The glossary defines many of the terms used in this guidance. In particular, the term instrument
refers to the actual questions or items contained in a questionnaire or interview schedule along
with all the additional information and documentation that supports the use of these items in
producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation
manual). The term conceptual framework refers to how items are grouped according to subconcepts
or domains (e.g., the item walking without help may be grouped with another item, walking with
difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept
of physical ability).
FDA's guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and
should be viewed only as recommendations, unless specific regulatory or statutory requirements
are cited. The use of the word should in Agency guidance documents means that something is
suggested or recommended but not required. 
First publication of the Draft Guidance by the Food and Drug Administration- February 2006.
1. Background
PRO instruments provide a means for measuring treat-
ment benefits by capturing concepts related to how a
patient feels or functions with respect to his or her health
or condition. The concepts, events, behaviors, or feelings
measured by PRO instruments can be either readily
observed or verified (e.g., walking) or can be non-observ-
able, known only to the patient and not easily verified
(e.g., feeling depressed). Although an assessment of symp-
tom improvement or pertinent function depends on
patient perception, historically these assessments were
often made by physicians who observed and interacted
with patients (depression scales, heart failure severity
scales, activities of daily living scales). Increasingly, such
assessments are based on PRO instruments. The purpose
of this guidance is to explain how the FDA evaluates such
instruments for their usefulness in measuring and charac-
terizing the benefit of medical product treatment.
The amount and kind of evidence that the FDA expects to
support a labeling claim measured by a PRO instrument is
the same as that required for any other labeling claim (see
appendix point 2). As with other labeling claims, the
determination of whether the PRO instrument supports
an effectiveness endpoint includes an assessment of the
ability of the PRO instrument to measure the claimed
treatment benefit and is specific to the intended popula-
tion and to the characteristics of the condition or disease
treated. Endpoints measured by PRO instruments are
most often used in support of claims that refer to a
patient's symptoms or ability to function.
Note, however, that PRO instruments that measure a sim-
ple concept may not be adequate to substantiate a more
complex claim. For example, PRO-based evidence of
improved symptoms alone generally is not sufficient to
substantiate a claim related to improvement in a patient's
ability to function or the patient's psychological state.
Rather, to substantiate such a general claim, a sponsor
should develop evidence to show not only a change in
symptoms, but how that change translates into other spe-
cific endpoints such as ability to perform activities of daily
living, or improved psychological state. Accordingly,
many PRO instruments are specifically designed to assess
both symptoms and other possible consequences of treat-
ment.
2. Patient-reported outcomes – regulatory 
perspective
2.1 Why use patient-reported outcome instruments in 
medical product development?
PRO instruments are included in clinical trials for new
medical products because (1) some treatment effects are
known only to the patient; (2) there is a desire to know
the patient perspective about the effectiveness of a treat-
ment; or (3) systematic assessment of the patient's per-
spective may provide valuable information that can be
lost when that perspective is filtered through a clinician's
evaluation of the patient's response to clinical interview
questions.
2.1.1 Some treatment effects are known only to the patient
For some treatment effects, the patient is the only source
of data. For example, pain intensity and pain relief are the
fundamental measures used in the development of anal-
gesic products. There are no observable or physical meas-
ures for these concepts.Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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2.1.2 Patients provide a unique perspective on treatment 
effectiveness
PRO instruments can be developed to measure what
patients want and expect from their treatment and what is
most important to them. When used to measure study
endpoints, PRO instruments can augment what is known
about the product based on the clinician perspective or
physiologic measures. This is important because improve-
ments in clinical measures of a condition may not neces-
sarily correspond to improvements in how the patient
functions or feels. For example, clinically meaningful
improvements in lung function as measured by spirome-
try may not correlate well with improvements in asthma-
related symptoms and their impact on a patient's ability
to perform daily activities.
2.1.3 Formal assessment may be more reliable than informal 
interview
Seeking information from patients about their symptoms
and the impact of those symptoms on function is not new.
In clinical practice, to obtain information known only to
the patients, clinicians often assess patient status by infor-
mally asking questions such as, "How many pillows do
you sleep on?" or, "Do you cough at night?" In clinical tri-
als, clinical assessments are formalized using specific
questions because a structured interview technique mini-
mizes measurement error and ensures consistency. Self-
completed questionnaires that are given directly to
patients without the intervention of clinicians are often
preferable to the clinician-administered interview and rat-
ing. Self-completed questionnaires capture directly the
patient's perceived response to treatment, without a third
party's interpretation, and may be more reliable than
observer-reported measures because they are not affected
by interobserver variability (which usually can be reduced
only by extensive training of observers). On the other
hand, PRO measures may be affected by interpatient vari-
ability if the instrument is not easily understood and com-
pleted by patients. Despite these concerns, well-developed
and adequately validated PRO instruments have been
shown to give answers that match the results obtained by
the most expert assessors (indeed, that is the usual way
their validity is assessed), and they appear to be particu-
larly suitable in studies involving many investigators.
2.2.1 A taxonomy of PRO instruments
PRO instruments measure concepts ranging from the state
of discrete symptoms or signs (e.g., pain severity or seizure
frequency) to the overall state of a condition (e.g., depres-
sion, heart failure, angina, asthma, urinary incontinence,
or rheumatoid arthritis), where both specific symptoms
and the impact of the condition (e.g., on function, activi-
ties, or feelings) can be measured, to feelings about the
condition or treatment (e.g., worry about getting worse,
having to avoid certain situations, feeling different from
others). PRO concepts can be general (e.g., improvement
in physical function, psychological well-being, or treat-
ment satisfaction) or specific (e.g., decreased frequency,
severity, or how bothersome the symptoms are). PRO
concepts can also be generic (i.e., applicable in a broad
scope of diseases or conditions as in the case of physical
functioning), condition-specific (e.g., asthma-specific), or
treatment-specific (e.g., measures of the toxicities of a
class of drugs such as interferons or opioids).
Some PRO instruments (e.g., health-related quality of life
instruments) attempt to measure both the effectiveness
and the side effects of treatment. PRO instruments that are
used in clinical trials to support effectiveness claims
should measure the adverse consequences of treatment
separately from the effectiveness of treatment.
The specific attributes of a PRO instrument will affect the
way it is developed, tested, and incorporated into a study
protocol to support conclusions of treatment benefit.
Table 1 lists some of the ways that PRO instruments can
vary in their objectives, uses, and characteristics. When the
FDA reviews a PRO instrument, our goal is to determine
whether its characteristics are appropriate and adequate to
support the study objectives.
3. Evaluating pro instruments
The adequacy of a PRO instrument as a measure to sup-
port medical product claims depends on its developmen-
tal history and demonstrated measurement properties.
Sponsors are encouraged to identify all endpoint meas-
urement goals early in product development, before stud-
ies are initiated, to provide the basis for product approval
or claim substantiation, allowing adequate time for PRO
instrument identification, modification, or if necessary,
new instrument development. A new PRO instrument can
be developed or an existing instrument can be modified if
sponsors determine that none is available, adequate, or
applicable to their product development program. When
considering an instrument that has been modified from
the original, the FDA generally plans to evaluate the mod-
ified instrument just as it would a new one. Therefore, in
such instances, we encourage sponsors to document the
original development processes, all modifications made,
and updated assessments of its measurement properties.
PRO instrument development, modification, and valida-
tion usually occur in a nonlinear fashion with a varying
sequence of events, simultaneous processes, or iterations.
This iterative process is presented as a wheel and spokes dia-
gram, shown in Figure 1, and discussed in detail in Sec-
tions 3.1. – 3.4. One or more parts of the original process
may be repeated in new PRO instrument development,
modification, or change in application of an existingHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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instrument. The following five sections describe the steps
usually taken in instrument development.
3.1 Development of the conceptual framework and 
identification of the intended application
During the planning of clinical development programs,
the FDA encourages sponsors to specify what claims they
seek, determine what concepts underlie those claims, and
then determine whether an adequate PRO instrument
exists to assess and measure those concepts. If it doesn't, a
new PRO instrument can be developed. The typical steps
involved in the selection or development of PRO instru-
ments for endpoints for clinical trials are described in the
following sections.
3.1.1 Identification of concepts and domains that are to be 
measured
One fundamental consideration in the development and
use of a PRO instrument is whether the instrument's con-
ceptual framework is appropriate and clearly defined. In
some cases, of course, the question of what to measure
may be obvious given the nature of the condition being
treated. Generally, however, instrument developers
choose the concepts and domains to be measured based
on patient interviews along with reviews of the literature
and expert opinion.
If documentation exists that a single item is a reliable and
valid measure of the concept of interest (e.g., pain sever-
ity), a one-item PRO instrument may be a reasonable
measure to support a claim concerning that concept. If the
concept of interest is general (e.g., physical function), a
single-item PRO instrument is usually unable to provide a
complete understanding of the treatment's effect because
a single item cannot capture all the domains of the general
concept. For this reason, single-item questions about gen-
eral concepts that imply multiple domains rarely provide
sufficient evidence to support claims about that general
concept. However, single-item questions about general
concepts can be useful to help interpret multi-item meas-
ures of the same concept and to determine whether
important items or domains of a general concept are miss-
ing (e.g., when results using single general questions do
not correlate with results using a multi-item question-
naire, this may be evidence that the questionnaire is not
capturing all the important domains of the concept con-
tained in the claim). Evidence from the patient cognitive
debriefing studies (i.e., the interview schedule, transcript,
Table 1: Taxonomy of PROs Used in Clinical Trials
Attribute Types
Intended use of the measure • To define entry criteria for study populations
• To evaluate efficacy
• To evaluate adverse events
Concepts measured • Overall health status
• Symptoms/signs, individually or as a syndrome associated with a medical condition
• Functional status (physical, psychological or social)
• Health perceptions (e.g., self-rating of health or worry about condition)
• Satisfaction with treatment or preference for treatment
• Adherence to medical treatment
Number of items • Single item for single concept
• Multiple items for single concept
• Multiple items for multiple domains within a concept
Intended measurement population or condition • Generic
• Condition-specific
• Population-specific
Mode of data collection • Interviewer-administered
• Self-administered, with or without supervision
• Computer-administered or computer-assisted
• Interactively administered (e.g., interactive voice response systems or Web-based systems)
Timing and frequency of administration • As events occur
• At regular intervals throughout a study
• Baseline and end of treatment
Types of scores • Single rating on a single concept (e.g., pain severity)
• Index – single score combining multiple ratings of related domains or independent concepts
• Profile – multiple uncombined scores of multiple-related domains
• Battery – multiple uncombined scores of independent concepts
• Composite – an index, profile, or battery
Weighting of items or concepts • All items and domains are equally weighted
• Items are assigned variable weights
• Domains are assigned variable weights
Response options • See Table 2 for examples of response options (types of PRO scales)Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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and listing of all concepts elicited by a single item) can be
used to determine when a concept is adequately captured
by a single item.
Multidomain PRO instruments can be used to support
claims about a general concept if the PRO instrument has
been appropriately developed and validated to measure
the important and relevant domains of the general con-
cept. The complex nature of multidomain PRO instru-
ments, however, often raises significant questions about
how to interpret and report results in a way that is not mis-
leading. For example, if improvements in a score for a gen-
eral concept (e.g., physical function) is driven by a single
responsive domain (e.g., symptom improvement) while
other important domains (e.g., physical abilities and
activities of daily living) did not show a response, a gen-
eral claim about improvements in physical function
would not be supported. The FDA intends to review all
evidence based on multidomain PRO measurements with
particular attention to the precise claim that is supported
by the results in the measured concepts or domains.
Documentation of the instrument development process
should reveal the means by which the domains were iden-
tified and named. This helps substantiate the adequacy of
the measure to support both the general concept and the
named domains. If a sponsor desires to support a claim
based on a portion of a multi-item instrument (a domain
or an item), the development and validation process
should ensure that the instrument supports the measure-
ment of the claimed concept. For example, some broad
health status measures include item lists of symptoms that
are summed in an overall score. Individual items that con-
tribute to the overall score (e.g., dyspnea) generally would
not support a dyspnea claim unless the items were devel-
oped to measure the claimed concept (e.g., the items val-
idly and reliably capture the impact of treatment on
dyspnea).
The PRO instrument development and modification process Figure 1
The PRO instrument development and modification process.
i. Identify Concepts and Develop
Conceptual Framework
Identify concepts and domains that are important to patients.
Determine intended population and research application.
Hypothesize expected relationships among concepts.
iii. Assess Measurement Properties
Assess score reliability, validity, and ability to detect change.
Evaluate administrative and respondent burden. Add, delete, or revise items.
Identify meaningful differences in scores. Finalize instrument formats,




recall period, and response scales.
Draft instructions.
Format instrument.
Draft procedures for scoring and
administration. Pilot test draft
instrument. Refine instrument and
procedures.





or method of administration. PROHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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For measures of general concepts, the FDA intends to
review how individual items are associated with each
other, how items are associated with each domain, and
how domains are associated with each other and the gen-
eral concept of interest. A diagram of the expected rela-
tionships among the PRO items and domains can help
reviewers evaluate these relationships. The diagram in Fig-
ure 2 depicts a generic example of a conceptual framework
where Domain Score 1, Domain Score 2, and Overall
Score each represent related but separate concepts. Items
in this diagram are aggregated into domains. In some
measures, domains can be aggregated into an overall
score. These expectations should be specified before the
validation process begins.
3.1.2 Identification of the intended application of the PRO instrument
It is also important to consider whether the development
and demonstrated measurement properties of a PRO
instrument provide an adequate basis for its planned use
in the study to support a claim. This is best established
before the study commences, but would in any case be
part of the FDA's application review. This is true whether
the PRO instrument is generic, intended for use across
multiple applications and populations, or specific, devel-
oped for a certain condition or population. The PRO
instrument can be developed for a variety of roles, includ-
ing defining trial entry criteria, including excessive sever-
ity, evaluating treatment benefit, or monitoring adverse
events.
3.1.3 Identification of the intended population
The FDA plans to compare the patient population used in
the PRO instrument development process to the study
populations enrolled in clinical trials to determine
whether the instrument is appropriate to that population
with respect to patient age, sex, ethnic identity, and cogni-
tive ability. Specific measurement considerations posed
by pediatric, cognitively impaired, or seriously ill patients
are discussed in Section 3.5.
3.2 Creation of the PRO instrument
When developing a PRO instrument, sponsors are encour-
aged to assess its adequacy in the context of the following
development processes.
3.2.1 Generation of items
It is important to consider the procedures used to identify
the set of items selected to measure a specific concept.
PRO instrument items can be generated from literature
reviews, transcripts from focus groups, or interviews with
patients, clinicians, family members, researchers, or other
sources. Depending on the conceptual framework, the
FDA may review whether appropriate individuals and
sources were used and how information gleaned from
those sources was used in the PRO instrument develop-
ment process.
PRO instrument item generation is incomplete without
patient involvement. Item generation generally incorpo-
rates the input of a wide range of patients with the condi-
tion of interest to represent appropriate variations in
severity and in population characteristics such as age or
sex. The FDA plans to review instrument development
(e.g., results from patient interviews or focus groups) to
determine whether adequate numbers of patients have
supported the opinion that the specific items in the instru-
ment are adequate and appropriate to measure the con-
cept.
Diagram of a conceptual framework Figure 2
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Items that ask patients to respond hypothetically or that
give patients the opportunity to respond on the basis of
their desired condition rather than on their actual condi-
tion are not recommended. For example, in assessing the
concept performance of daily activities, it is more appropri-
ate to ask whether or not the respondent performs specific
activities (and if so, with how much difficulty) than
whether or not he or she can perform daily activities
(because patients may report they are able to perform a
task even when they never do so). Of course, it would be
critical to know that each item refers to something that
patients actually do.
It is also important to consider all of the item generation
techniques used, including any theoretical approach used,
the populations studied, sources of items, selection and
reduction of items, cognitive debriefing interviews, pilot
testing, importance ratings, and quantitative techniques
for item evaluation such as factor analysis and item-
response analysis.
3.2.2 Choice of the data collection method
Sponsors should consider the method of data collection
and all procedures and protocols associated with instru-
ment administration, including instructions to interview-
ers, instructions for self-administration, instructions for
supervising self-administration, case report forms or
examples of electronic PRO instruments, and other spe-
cial considerations specific to the mode of administration
including data quality control procedures. Modes of
administration include interview, paper-based, electronic,
Web-based, and interactive voice response formats. The
FDA intends to review the comparability of data obtained
when using multiple modes of administration to deter-
mine whether pooling of results from the multiple modes
is appropriate.
3.2.3 Choice of the recall period
Sponsors should also evaluate the rationale and the
appropriateness of the recall period for a PRO instrument.
To this end, it is important to consider patients' ability to
accurately recall the information requested as proposed.
The choice of recall period that is most suitable depends
on the purpose and intended use of the instrument, the
characteristics of the disease/condition, and the treatment
to be tested. When evaluating PRO-based claims, the FDA
intends to review the study protocol to determine what
steps were taken to ensure that patients understand the
appropriate recall period. If a patient diary or some other
form of unsupervised data entry is used, the FDA plans to
review the protocol to determine what measures are taken
to ensure that patients make entries according to the study
design and not, for example, just before a clinic visit when
their reports will be collected.
PRO instruments that require patients to rely on memory,
especially if they must recall over a period of time, or to
average their response over a period of time may threaten
the accuracy of the PRO data. It is usually better to con-
struct items that ask patients to describe their current state
than to ask them to compare their current state with an
earlier period or to attempt to average their experiences
over a period of time.
3.2.4 Choice of response options
It is also important to consider whether the response
options are consistent with the purpose and intended use
of the PRO instrument. Table 2 describes the types of
response options that are typically used in clinical trials.
Response choices are generally considered appropriate
when:
Table 2: Types of Response Options
Type Description
Visual analog scale (VAS) A line of fixed length (usually 100 mm) with words that anchor the scale at the extreme ends and no words 
describing intermediate positions. Patients are instructed to place a mark on the line corresponding to their 
perceived state. These scales often produce a false sense of precision.
Anchored or categorized VAS A VAS that has the addition of one or more intermediate marks positioned along the line with reference terms 
assigned to each mark to help patients identify the locations (e.g., half-way) between the ends of the scale.
Likert scale An ordered set of discrete terms or statements from which patients are asked to choose the response that best 
describes their state or experience.
Rating scale A set of numerical categories from which patients are asked to choose the category that best describes their state 
or experience. The ends of rating scales are anchored with words but the categories do not have labels.
Event log Specific events are recorded as they occur using a patient diary or other reporting system (e.g., interactive voice 
response system)
Pictorial scale A set of pictures applied to any of the other types of response options. Pictorial scales are often used in pediatric 
questionnaires but also have been used for patients with cognitive impairments and for patients who are otherwise 
unable to speak or write.
Checklist Checklists provide a simple choice between a limited set of options, such as Yes, No, and Don't know. Some 
checklists ask patients to place a mark in a space if the statement in the item is true. Checklists are reviewed for 
completeness and nonredundancy.Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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• Wording used in responses is clear and appropriate (e.g.,
anchoring a scale using the term normal  assumes that
patients understand what is normal).
• Responses are appropriate for the intended population.
For example, patients with visual impairment may find
the VAS difficult to complete.
• Responses offer a clear distinction between choices (e.g.,
patients may not distinguish between intense and severe if
both are offered as response choices to describe their
pain).
• Instructions to patients for completing the question-
naire and selecting response options are adequate.
• The number of response options is justified.
• Response options are appropriately ordered and appear
to represent equal intervals.
• Response options avoid potential ceiling or floor effects
(e.g., introducing more categories to capture worsening or
improvement so that fewer patients respond at the top or
bottom of the response continuum).
• Response options do not bias the direction of responses
(e.g., offering one negative choice, one neutral choice, and
two or more positive choices on a scale makes it more
likely for patients to respond that they feel or function bet-
ter).
3.2.5 Evaluation of patient understanding
Sponsors are encouraged to examine the procedures used
with patients to determine readability and understanding
of the items included in the PRO instrument. The FDA's
evaluation of these procedures is likely to include a review
of a cognitive debriefing report containing the readability
test used, the script used in patient cognitive debriefing
interviews, the transcript of the interviews, the analysis of
the interview results, and the actions taken to delete or
modify an item in response to the cognitive debriefing
interview or pilot test results.
3.2.6 Development of format, instructions, and training
PRO study results can vary according to the instructions to
patients or the training given to the interviewer or persons
supervising PRO data collection. Sponsors should con-
sider all PRO instrument instructions and procedures con-
tained in publications and user manuals provided by
developers, including procedures for reviewing completed
questionnaires and re-administration to avoid missing
data or clarify responses. Other important considerations
include the format of the questionnaire, the final wording
of PRO instruments as implemented in clinical trials, and
any potentially important changes in presentation or for-
mat. Examples of changes that can alter the way that
patients respond to the same set of questions include:
• Changing an instrument from paper to electronic format
• Changing the timing of or procedures for PRO instru-
ment administration within the clinic visit
• Changing the order of items or deleting portions of a
questionnaire
• Changing the instructions or the placement of instruc-
tions within the PRO instrument
It is important that the PRO instrument format used in the
clinical trial be consistent with the format that is used in
the instrument validation process. Format  refers to the
exact appearance of the instrument. Instrument format is
specific to the mode of administration, including paper
and pencil, interviewer-administered or supervised, or
electronic data collection. The FDA plans to review the
PRO instrument in the format used in the clinical trial
case report forms, including the order and numbering of
items, the presentation of response options in single
response or grid formats, the grouping of items, patterns
for skipping questions that are not applicable, and all
instructions to patients in the interview schedule or on the
questionnaire.
The FDA recommends that the PRO instrument develop-
ment process includes the generation of a user manual
that specifies how to incorporate the instrument into a
clinical trial in a way that minimizes administrator bur-
den, patient burden, missing data, and poor data quality.
3.2.7 Identification of preliminary scoring of items and domains
For each item, numerical scores are generally assigned to
each answer category based on the most appropriate scale
of measurement for the item (e.g., nominal, ordinal,
interval, or ratio scales). The FDA intends to consider
whether a PRO measure conforms to assumptions that the
response choices represent appropriate intervals by
reviewing distributions of item responses.
A scoring algorithm creates a single score from multiple
items. Equally weighted scores for each item are appropri-
ate only when the responses to the items are relatively
uncorrelated. Otherwise, the assignment of equal weights
will overweight correlated items and underweight inde-
pendent items. Even when items are uncorrelated, assign-
ing equal weights to each item may overweight certain
items if the number of response options or the values
associated with response options varies by item. The sameHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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weighting concerns apply with added complexity when
combining domain scores into a single overall score.
When empirically determined patient preference ratings
are used to weight items or domains, the FDA also intends
to review the composition of samples and the process
used to determine the preference weights. Because prefer-
ence weights are often developed for use in resource allo-
cation (e.g., as in cost-effectiveness analysis that may use
predetermined community weights), it is tempting to use
those same weights in the clinical trial setting to demon-
strate treatment benefit. However, this practice is discour-
aged unless the relationship of the preference weights to
the intended study population is known and found ade-
quate and appropriate.
3.2.8 Assessment of respondent and administrator burden
Undue physical, emotional, or cognitive strain on patients
are burdens that will generally decrease the quality and
quantity of PRO data. Factors that can contribute to
respondent burden include the following:
• Length of questionnaire or interview
• Formatting
• Font size too small to read easily
• New instructions for each item
• Words or sentence structures that require a technical
knowledge or developmental level beyond that of the
patients in the trials
• Requirement that patients consult records to complete
responses
• Privacy of the setting in which the PRO is completed
(e.g., not providing a private space for patients to com-
plete questionnaires containing sensitive information
about their sexual performance or substance abuse his-
tory)
• Inadequate time to complete questionnaires or inter-
views
• Literacy level too high for population
• Questions that patients are unwilling to answer
• Perception by patients that the interviewer wants or
expects a particular response
The degree of respondent burden that is acceptable for
instruments in clinical trials depends on the frequency
and timing of PRO assessments in a protocol and on the
severity of the illness or toxicity of the treatment studied.
For example, if the questionnaire contains instructions to
skip one or more questions based on responses to a previ-
ous question, respondents may fail to understand what is
required and make errors in responding or find the assess-
ment too complicated to complete. Sponsors should con-
sider missing data and the refusal rate as possible
indications of unacceptable patient burden or inappropri-
ate items or response options.
3.2.9 Confirmation of the conceptual framework and finalization of 
the instrument
The FDA intends to examine the final version of an instru-
ment in light of its development history, including docu-
mentation of the complete list of items generated and the
reasons for deleting or modifying items, as illustrated in
Table 3. It will be important to determine from empirical
Table 3: Common Reasons for Changing PRO Instruments During Initial Development
Item Property Reason for Change or Deletion
Clarity or relevance • Reported as not relevant by a large segment of the population of interest
• Generates an unacceptably large amount of missing data points
• Generates many questions or requests for clarification from patients as they complete the PRO instrument
• Patients interpret items and responses in a way that is inconsistent with the conceptual framework
Response range • A high percent of patients respond at the floor (worst end of the response scale) or ceiling (optimal end of the 
response scale)
• Patients note that none of the response choices apply to them
• Item means are highly skewed
Variability • All patients give the same answer (i.e., no variance)
• Most patients choose only one of the response choices
• Differences among patients are not detected when important differences are known
Reproducibility • Unstable scores over time when there is no logical reason for variation from one assessment to the next
Inter-item correlation • Item uncorrelated with other items in the same concept of interest
Ability to detect change • Item is nonresponsive (i.e., does not change when there is a known change in the concepts of interest)
Item discrimination • Item is highly correlated with measures of concepts other than the one it is intended to measure
Redundancy • Item duplicates information collected with other items that have equal or better measurement propertiesHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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data submitted whether the conceptual framework (e.g.,
the expected relationships between items, domains, and
measurement concepts as diagrammed in Figure 2) have
been demonstrated.
3.3 Assessment of measurement properties
The FDA generally intends to review a PRO instrument
for: reliability, validity, ability to detect change, and inter-
pretability (e.g., minimum important difference). The
FDA plans to review the measurement properties that are
specific to the documented conceptual framework, con-
firmed scoring algorithm, administration procedures, and
questionnaire format in light of the study population,
study design, and statistical analysis plan. The sociodemo-
graphic and medical characteristics of any sample used to
develop or validate a PRO instrument determine its
appropriateness for future clinical study settings. (See
Table 4.)
3.3.1 Evaluation of reliability
Because clinical trials involve change over time, the ade-
quacy of a PRO instrument for use in a clinical trial
depends on its reliability. Because clinical trials are
intended to provide unbiased estimates of true treatment
impact, systematic and/or other changes in measurement
methods may undermine the purpose of the trial.
Test-retest reliability is the most important type of reliabil-
ity for PRO instruments used in clinical trials. Test-retest is
most informative when the time interval chosen between
the test and retest is appropriate for identifying stability in
reference to the clinical trial protocol.
Internal consistency reliability, in the absence of test-
retest reliability, does not generally constitute sufficient
evidence of reliability for clinical trial purposes. When
PRO instruments are interviewer-administered, inter-
interviewer reproducibility is critical.
3.3.2 Evaluation of validity
The FDA recognizes that the validation of an instrument is
an ongoing process and that validity relates to both the
instrument itself and how it is used. Sponsors should con-
sider a PRO endpoint for evidence of content-related
validity, the instrument's ability to measure the stated
concepts, and the instrument's ability to predict future
outcomes, as illustrated in Table 4.
If instrument developers expected the instrument to give
results for the measured concept similar to those meas-
ured by existing PRO or non-PRO measures (e.g., physical
or physician-based measures), the FDA is interested in
documented demonstration of those relationships to
determine whether the instrument convincingly measures
that concept and can therefore support a claim about that
concept. If developers expected the instrument to discrim-
inate between patient groups (e.g., between patients with
different levels of severity), the FDA is interested in evi-
dence that shows the instrument meaningfully discrimi-
nates.
In some cases, some types of validity testing are not possi-
ble due to the nature of the concept to be measured. In
such instances, the FDA generally plans to review the
cumulative evidence for the appropriate use of the meas-
ure and apply it to the interpretation of clinical study
results.
3.3.3 Evaluation of ability to detect change
When a concept is expected to change, the values for the
PRO instrument measuring that concept should change. If
there is clear evidence that patient experience relative to
the concept has changed, but the PRO scores do not
change, the validity of the PRO instrument should be
questioned. If there is evidence that PRO scores are
affected by changes that are not specific to the concept of
interest, the validity of the PRO instrument should be
questioned.
The ability of an instrument to detect change influences
the sample size needed to evaluate the effectiveness of
treatment. The extent to which the PRO instrument's abil-
ity to detect change varies by important patient subgroups
(e.g., sex, race, age, or ethnicity) can affect clinical trial
results. It is important to identify any important subgroup
differences in ability to detect change so that these differ-
ences can be taken into account in assessing results.
3.3.4 Choice of methods for interpretation
The following sections describe some of the methods that
have helped sponsors and the FDA interpret clinical trial
results based on PRO endpoints.
3.3.4.1 Defining a minimum important difference
Many PRO instruments are able to detect mean changes
that are very small; accordingly it is important to consider
whether such changes are meaningful. Therefore, it is
appropriate for a critical distinction to be made between
the mean effect seen (and what effect might be considered
important) and a change in an individual that would be
considered important, perhaps leading to a definition of a
responder. For many widely used measures (pain, treadmill
distance, HamD), the ability to show any  difference
between treatment groups has been considered evidence
of a relevant treatment effect. If PRO instruments are to be
considered more sensitive than past measures, it can be
useful to specify a minimum important difference (MID)
as a benchmark for interpreting mean differences. An MID
is usually specific to the population under study.Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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Table 4: Measurement Properties Reviewed for PRO Instruments Used in Clinical Trials
Measurement
Property
Test What is Assessed FDA Review Considerations
Reliability Test-retest Stability of scores over time when no 
change has occurred in the concept of 
interest
Does the PRO instrument reliably 
measure the concepts it was designed to 
measure?
Internal consistency Whether the items in a domain are 
intercorrelated, as evidenced by an 
internal consistency statistic (e.g., 
coefficient alpha)





Agreement between responses when 
the PRO is administered by two or 
more different interviewers
What was the quality of the evidence of 
reliability?
Validity Content-related Whether items and response options 
are relevant and are comprehensive 
measures of the domain or concept
Do items in the verbatim copy of the 
PRO instrument appear to measure the 
concepts they are intended to measure 
in a useful way?
Have patients similar to those 
participating in the clinical trial 
confirmed the completeness and 
relevance of all items?
Ability to measure the concept 
(also known as construct-related 
validity; can include tests for 
discriminant, convergent, and 
known-groups validity)
Whether relationships among items, 
domains, and concepts conform to what 
is predicted by the conceptual 
framework for the PRO instrument 
itself and its validation hypotheses.
Do observed relationships between the 
items and domains confirm the 
hypotheses in the conceptual 
framework? Do results compare 
favorably with results from a similar but 
independent measure?
Do results distinguish one group from 
another based on a prespecified variable 
that is relevant to the concept of 
interest?
Ability to predict future outcomes 
(also known as predictive validity)
Whether future events or status can be 
predicted by changes in the PRO scores
Do PRO scores predict subsequent 
events or outcomes accurately?
Ability to detect change Includes calculations of effect size 
and standard error of 
measurement among others
Whether PRO scores are stable when 
there is no change in the patient, and 
the scores change in the predicted 
direction when there has been a notable 
change in the patient as evidenced by 
some effect size statistic. Ability to 
detect change is always specific to a time 
interval.
Has ability to detect change been 
demonstrated in a comparative trial 
setting, comparing mean group scores 
or proportion of patients who 
experienced a response to the 
treatment?
Has ability to detect change been 
assessed for the time interval 
appropriate to study?
Interpretability Smallest difference that is 
considered clinically important; 
this can be a specified difference 
(the minimum important 
difference (MID)) or, in some 
cases, any detectable difference. 
The MID is used as a benchmark 
to interpret mean score 
differences between treatment 
arms in a clinical trial
Difference in mean score between 
treatment groups that provides 
convincing evidence of a treatment 
benefit. Can be based on experience 
with the measure using a distribution-
based approach, a clinical or nonclinical 
anchor, an empirical rule, or a 
combination of approaches. The 
definition of an MID using a clinical 
anchor is sometimes called an MCID.
The FDA is specifically requesting 
comment on appropriate review of 
derivation and application of an MID in 
the clinical trial setting.
Responder definition – used to 
identify responders in clinical trials 
for analyzing differences in the 
proportion of responders between 
treatment arms
Change in score that would be clear 
evidence that an individual patient 
experienced a treatment benefit. Can be 
based on experience with the measure 
using a distribution-based approach, a 
clinical or nonclinical anchor, an 
empirical rule, or a combination of 
approaches.
The FDA is specifically requesting 
comment on appropriate review of 
derivation and application of responder 
definitions when used in clinical trials.Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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The FDA has reviewed MIDs derived in many ways. Exam-
ples include:
• Mapping changes in PRO scores to clinically relevant
and important changes in non-PRO measures of treat-
ment outcome in the condition of interest (e.g., when
PRO measures of asthma or COPD are mapped to spirom-
etry scores).
• Mapping changes in PRO scores to other PRO scores to
arrive at an MID that is appreciable to patients (e.g., when
multi-item PROs are mapped to a single question asking
the patient to rate his or her global impression of change
since the start of treatment). A problem with this
approach is that it uses individual rates to reach a conclu-
sion about mean effects. It may be more useful to look at
the distribution of individual effects in treatment and con-
trol groups.
• Using a distribution-based approach (e.g., defining the
MID as 0.5 times the standard deviation). This, of course,
may bear no relation to the patient's assessment and is
usually inadequate in isolation.
• Using an empirical rule (e.g., 8 percent of the theoretical
range of scores). Again, this arbitrary approach does not
take into account patient preferences or assessment.
If an MID is to be applied to clinical study results, it is gen-
erally helpful to use a variety of methods to discover
whether concordance among methods confirms the
choice of an MID (see appendix point 3).
3.3.4.2 Definition of responders
There may be situations where it is more reasonable to
characterize the meaningfulness of an individual's
response to treatment than a group's response, and there
may be interest in characterizing an individual patient as
a responder to treatment, based upon prespecified criteria
backed by empirically derived evidence supporting the
responder definition as a measure of benefit. Such exam-
ples include categorizing a patient as a responder based
upon a prespecified change from baseline on one or more
scales; a change in score of a certain size or greater (e.g., a
2-point change on an 8-point scale); or a percent change
from baseline (see appendix point 4).
3.4 Modification of an existing instrument
When a PRO instrument is modified, additional valida-
tion studies may be needed to confirm the adequacy of
the modified instrument's measurement properties. The
extent of additional validation recommended depends on
the type of modification made. For example, small non-
randomized studies may be adequate to assess the results
of changing a response scale from vertical to horizontal.
On the other hand, if the PRO instrument is to be used in
an entirely new population of patients, a small rand-
omized study to ascertain the measurement properties in
the new population may minimize the risk that the instru-
ment will not perform adequately in a phase 3 study.
The FDA intends to consider a modified instrument as a
different instrument from the original and will consider
measurement properties to be version-specific. The FDA
recommends additional validation to support the devel-
opment of a modified PRO instrument when one or more
of the following modifications occur.
3.4.1 Revised measurement concept
An instrument that is developed and validated to measure
one concept is used to measure a different concept. For
example:
• A single domain from a multiple domain PRO is admin-
istered without the other domains
• Response options are changed to assess a different qual-
ity (e.g., frequency versus how bothersome)
• An index or composite score is used to summarize mul-
tiple PRO concepts/domains when existing validation
applies only to concept/domain-specific scores
• Items from an existing PRO instrument are used to cre-
ate a new instrument
• One or more items from an existing instrument are used
to support a claim for a concept the items were not devel-
oped to measure
3.4.2 Application to a new population or condition
An instrument developed for use in one population or
condition is used in a different patient population or con-
dition. For example:
• Patients in the proposed trial have a disease, condition,
or severity level that is different from that of the patient
population used for instrument development and valida-
tion
• Patients in the proposed trial differ in age, gender, race,
or developmental or life stage from those for instrument
development and validation
3.4.3 Changed item content or instrument format
An instrument is altered in item content or format. This
includes changes in the following:
• Number of items (more or fewer) used to assess a con-
cept or domainHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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• Wording or placement of instructions
• Wording or order of the items
• Wording, scaling, ordering, or number of response
options
• Recall period associated with an item
• Point of reference for comparison for an item or domain
• Weighting of items
• Scoring (including creation of summary scores, sub-
domain scores, or cut-points)
• Any changes that could alter the patient's interpretation
of the instructions, items, or response options
3.4.4 Changed mode of administration
An instrument's data collection mode is altered. For exam-
ple:
• An interviewer-administered or supervised question-
naire is modified for self-administration (skip patterns
can be a problem in this situation)
• Paper-and-pencil self-administered PRO is modified to
be administered by computer or other electronic device
(e.g., computer adaptive testing, interactive voice
response systems, Web-based questionnaire administra-
tion, computer)
• Instructions or procedures for administration within a
trial differ from those used in validation studies (can alter
the meaning of the responses from that of the original ver-
sion)
3.4.5 Changed culture or language of application
An instrument developed in one language or culture is
adapted or translated for use in another language or cul-
ture. The FDA recommends that sponsors provide evi-
dence that the methods and results of the translation
process were adequate to ensure that the validity of the
responses is not affected. Some examples include the fol-
lowing:
• PRO instruments are developed initially in one lan-
guage, culture, or ethnic group and are used subsequently
in another
• PRO instruments developed and validated outside the
United States are applied to the U.S. population
Sponsors should consider whether generally accepted
standards for translation and cultural adaptation have
been used to support the validity of data from a trans-
lated/adapted PRO instrument, including but not
restricted to the following:
• The background and experience of the persons involved
in the translation/adaptation
• The translation/adaptation methodology used
• The harmonization of different versions
• The evidence that measurement properties for translated
versions are comparable
3.4.6 Other changes
Other changes to the PRO instrument or the way in which
it is assessed that may necessitate additional validation
include:
• The PRO instrument was not developed and validated
for use in a clinical trial
• A PRO instrument developed and previously used as a
stand-alone assessment is included as a part of a battery of
measures
• A PRO developed to measure a treatment benefit is sub-
sequently used to measure a decrement as interpreted by
a score change in the opposite direction
3.5 Development of PRO instruments for specific 
populations
Measurement of PRO concepts in children and youth, and
in patients who have cognitive impairment, introduces
challenges in addition to those already mentioned. These
are discussed in the following sections.
3.5.1 Children and youth
In general, the review issues related to the development
and validation of pediatric PRO instruments are similar to
those detailed for adults. It is important that PRO instru-
ments developed for adults are not used in pediatric pop-
ulations unless the measurement properties are similar in
all age groups tested. We recommend that instruments
intended for use in pediatric populations be rigorously
developed and validated according to the principles
described earlier. Additional review issues for PRO instru-
ments applied in children and youth include age-related
vocabulary, language comprehension, comprehension of
the health concept measured, and duration of recall.
Instrument development and validation testing within
fairly narrow age groupings is important to account for
developmental differences and to determine the lower ageHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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limit at which children can understand the questions and
provide reliable and valid responses that can be compared
across age categories.
3.5.2 Patients cognitively impaired or unable to communicate
Over the course of some clinical trials, it can be antici-
pated that patients may become too ill to complete a
questionnaire or to respond to an interviewer. In such
cases, proxy reporting may help to prevent missing data.
When this situation is anticipated, the FDA encourages
the inclusion of proxy reports in parallel with patient self-
report from the beginning of the study (i.e., even before
the patient is no longer able to answer independently) so
that the relationship between the patient reports and the
proxy reports can be assessed.
4. Study design
The same study design principles that apply to other end-
point measures apply to PROs. This section, therefore,
focuses primarily on issues unique to PROs.
4.1 General protocol considerations
If the goal of PRO measurement is to support claims, we
recommend that measurement of the PRO concept be
clearly stated as a specific study objective. It is important
that the protocol include the exact format and version of
the specific PRO instrument to be administered. In the
process of considering the NDA/BLA/PMA or NDA/BLA/
PMA supplement, the FDA intends to compare both the
planned and actual use of the PRO instrument and its
analysis.
4.1.1 Blinding and randomization
Because responses to PRO measures are subjective, repre-
senting a patient's impression, open-label studies, where
patients and investigators are aware of assigned therapy,
are rarely credible. Patients who know they are in an active
treatment group may overestimate benefit while those
who know they are not receiving active treatment may
underreport any improvement actually experienced. Every
effort should be made to assure that patients are masked
to treatment assignment throughout the trial. If the treat-
ment has obvious effects, blinding may be difficult. The
impact of possible unblinding is important to consider in
the interpretation of study results.
The importance of blinding can be determined, in part, by
the characteristics of the PRO instrument used. For exam-
ple, questions that ask how patients' current status com-
pares to baseline seem likely to be more influenced by
unblinding (optimism can readily be expressed as a favo-
rable comparison) than questions that ask about current
status (which requires a current assessment, not a state-
ment about duration). Questions that ask for current sta-
tus, or PRO instruments that ask many questions, are
harder to answer in a biased way when previous answers
are not available. For the same reasons, allowing patients
access to previous responses can bias results when
unblinding is a possibility. This is, however, an area that
could benefit from rigorous study.
There are certain situations, particularly in the develop-
ment of medical devices, where blinding is not feasible
and other situations where there is no reasonable control
group (and therefore no randomization). When a PRO
instrument appears useful in assessing patient benefit in
those situations, the FDA encourages sponsors to confer
with the appropriate review division.
4.1.2 Clinical trial quality control
Study quality can be optimized at the design stage by spec-
ifying procedures to minimize inconsistencies in trial con-
duct. Examples of standardized instructions and processes
that may appear in the protocol include:
• Standardized training and instructions to patients for
self-administered PRO instruments
• Standardized interviewer training and interview format
for PRO instruments administered in an interview format
• Standardized instructions for the clinical investigators
regarding patient supervision, timing and order of ques-
tionnaire administration during or outside the office visit,
processes and rules for questionnaire review for complete-
ness, and documentation of how and when data are filed,
stored, and transmitted to or from the study site
4.1.3 Designing the trial to avoid data missing due to withdrawal 
from exposure
Sometimes patients fail to report for visits, fail to com-
plete questionnaires that contain response endpoints, or
withdraw from assigned treatment prior to planned com-
pletion of a clinical trial without contributing PRO infor-
mation. The resulting missing data can introduce bias and
interfere with the ability to compare effects in the test
group with the control group because only a subset of the
initial randomized population contributes, and these
patient groups may no longer be comparable. Missing
data is a major challenge to the success and interpretation
of any clinical trial.
The protocol can increase the likelihood that a trial will
still be informative by establishing plans for gathering all
treatment-related reasons for patients withdrawing from a
trial and by trying to minimize patient dropouts prior to
trial completion. We recommend the study protocol
describe how missing data will be handled in the analysis.
It could also establish a process by which PRO measure-
ment is ascertained before or shortly after patient with-Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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drawal from treatment exposure due to lack of efficacy or
toxicity.
4.2 Frequency of measurements
The frequency of PRO assessment depends on the natural
history of the disease and the nature of the treatment.
Some diseases, conditions, or study designs may necessi-
tate more than one baseline assessment and several PRO
assessments during treatment. The frequency of PRO
assessment should correspond with the demonstrated
measurement properties of the instrument and with the
planned data analysis.
4.3 Duration of study
It is also important to consider whether the duration of
the study is of adequate length to support the proposed
claim and assess a durable outcome in the disease or con-
dition being studied. Generally, duration of follow-up
with a PRO assessment should be at least as long as for
other measures of effectiveness. It should be noted, how-
ever, that the study duration appropriate for the PRO-
related study objective may not be the same as the study
duration for other study endpoints. In a trial for a progres-
sive disease where the PRO concept of interest does not
change until after the follow-up required for other clinical
efficacy parameters, longer study duration can be indi-
cated.
4.4 Design considerations for multiple endpoints
The hierarchy of endpoints is determined by the stated
objectives of the trial and the clinical relevance and
importance of each specific measure independently and
in relationship to each other. A PRO instrument could be
the primary endpoint measure of the study, a co-primary
endpoint measure in conjunction with other objective or
physician-rated measurements, or a secondary endpoint
measure whose analysis would be considered according to
a hierarchical sequence. The FDA recommends that the
study protocol define the study endpoint measures and
the criteria for the statistical analysis and interpretation of
results, including a clear specification of the conditions
for a positive study conclusion.
4.5 Planning for study interpretation
The FDA recommends that sponsors discuss with the
appropriate review division how best to plan for the inter-
pretation of study findings. In some cases, the FDA may
request an a priori definition of the minimum observed
difference between treatment group means (i.e., MID)
that will serve as a benchmark to interpret whether study
findings are conclusive. In other cases, the FDA may
request an a priori definition of a treatment responder that
can be applied to individual patient changes over time.
Prespecification of methods for interpretation is particu-
larly important with new or unfamiliar instruments or
when patient dropouts, withdrawals from exposure, or
missing data are expected (e.g., in studies where repeated
PRO measurement is planned). See Section 5.5 for guid-
ance on interpretation considerations for a study's statisti-
cal analysis plan.
4.6 Specific concerns when using electronic PRO 
instruments
When electronic PRO instruments are used, sponsors
should plan carefully to ensure that FDA regulatory
requirements are met for sponsor and investigator record
keeping, maintenance, and access (see appendix point 5).
These responsibilities are independent of the method
used to record clinical trial data and, therefore, apply to
electronic PRO data. Sponsors are responsible for provid-
ing investigators with the information they need to con-
duct the investigation properly, for monitoring the
investigation, for ensuring that the investigation is con-
ducted in accordance with the investigational plan, and
for permitting the FDA to access, copy, and verify records
and reports relating to the investigation.
The principal record keeping requirements for clinical
investigators include the preparation and maintenance of
adequate and accurate case histories (including the case
report forms and supporting data), record retention, and
provision for the FDA to access, copy, and verify records
(i.e., source data verification). The investigator's responsi-
bility to control, access, and maintain source documenta-
tion can be satisfied easily when paper PRO instruments
are used, because the subject usually returns the diary to
the investigator who either retains the original or a certi-
fied copy as part of the case history. The use of electronic
PRO instruments, however, may pose a problem if direct
control over source data is maintained by the sponsor or
the contract research organization and not by the clinical
investigator. The FDA considers the investigator to have
met his or her responsibility when the investigator retains
the ability to control and provide access to the records that
serve as the electronic source documentation for the pur-
pose of an FDA inspection. The FDA recommends that the
study protocol, or a separate document, clearly specify
how the electronic PRO source data will be maintained.
In addition, the FDA has previously provided guidance to
address the use of computerized systems to create, mod-
ify, maintain, archive, retrieve, or transmit clinical data to
the agency (see appendix point 6) and to clarify the
requirements and application of 21 CFR part 11 (see
appendix point 7). Because electronic PRO data (includ-
ing data gathered by personal digital assistants or phone-
based interactive voice recording systems) are part of the
case history, the FDA expects electronic PRO data to be
consistent with the data standards described in that guid-
ance. Sponsors should plan carefully to establish appro-Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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priate system and security controls, as well as
cybersecurity and system maintenance plans that address
how to ensure data integrity during network attacks and
software updates.
Sponsors should also plan to avoid the following (see
appendix point 8)
• Direct PRO data transmission from the PRO data collec-
tion device to the sponsor (i.e., the sponsor should not
have exclusive control of the source document)
• The existence of only one database without backup (i.e.,
risk of data corruption or loss during the trial with no way
to reconstitute or verify the data)
• Removal of investigator accountability for confirming
the accuracy of the data
• Loss of adverse event data
• Access to unblinded data
• Inability of an FDA investigator to inspect, verify, and
copy the data at the clinical site during an inspection
• An insecure system that allows for easily alterable
records.
5. Data analysis
Incorporating PRO instruments as study endpoint meas-
ures introduces challenges in the analysis of clinical trial
data. Some of these challenges are discussed in the follow-
ing sections.
5.1 General statistical considerations
The statistical analysis considerations for PRO endpoints
are not unlike statistical considerations for any other end-
point used in drug development (see appendix point 9).
We recommend that the principal features of the planned
statistical analysis of the data be described in the statistical
section of the protocol and in a detailed elaboration of the
analysis often called the Statistical Analysis Plan (SAP).
The FDA intends to determine the adequacy of study data
to support claims in light of the prespecified method for
endpoint analysis. Unplanned or post hoc statistical anal-
yses are usually viewed as exploratory and, therefore, una-
ble to serve as the basis of a claim of effectiveness.
5.2 Statistical considerations for using multiple endpoints
It is important that the study protocol specify all end-
points that will be considered, including each domain
score targeted to support a specific claim. The SAP should
describe the planned primary analysis in detail, noting
whether the endpoint will be analyzed as a continuous
variable (mean scores), dichotomous variable (success/
failure), or some graded response, the primary and sec-
ondary endpoints, corrections for multiplicity, and the
specific statistical methods planned.
In some situations, the SAP can specify that two or more
variables must be statistically demonstrated to be superior
to control group findings to support a claim. This may be
the case, for example, when a clinician-reported endpoint
and a patient-reported endpoint both need to be shown
better than the control. Control for multiplicity (i.e.,
adjustment of the Type I error) generally is not a concern
when all endpoints are shown to be superior to those of
the comparison group, but we recommend carefully con-
sidering the impact of choosing multiple primary end-
points on Type II error and sample size. The sample size
of the trial may be affected by how many endpoints are
measured, the overall strategy planned to integrate all
endpoints in the SAP, and the decision rule for declaring
a successful study outcome.
Because each PRO item or domain often can represent an
endpoint that could imply a distinct claim on its own, we
recommend careful planning to avoid substantial
increases in Type 1 error from multiple endpoints. If it is
important in a study to demonstrate that PROs have the
same directional effect as other measures of treatment
benefit, then statistical procedures can be considered to
minimize the impact of multiple endpoint comparisons.
There is no single best statistical procedure for multiplicity
adjustment because the choice of procedure depends
upon the study objectives, the most important endpoints
among the collection, and other considerations. Some of
the statistical procedures that can be useful for a more effi-
cient analysis approach include methods that prespecify a
sequence or order of the testing or that have a hierarchy of
comparisons that first need to be satisfied before others
are considered for testing (i.e., closed testing procedures,
gatekeeper strategies). Generally, these statistical methods
are less conservative than the classical Bonferroni or other
statistical multiplicity adjustments that are used to control
false positive conclusions from a family of eligible
hypotheses. Another reason to consider less conservative
methods is to adjust for what are often strong correlations
among the endpoints (causing a Bonferroni adjustment to
be too conservative). These strategies reduce the need for
more stringent statistical tests for the subsequent end-
points, but do not allow statistical testing for endpoint
combinations not prespecified.
A multidomain PRO measure can successfully support a
claim based on one or a subset of the domains measured
if an a priori analysis plan prespecifies the domains that
will be targeted as endpoints for the study. However, dem-Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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onstration that only a subset of domains is affected by
treatment (e.g., the physical function domain) generally
will not support a general claim (e.g., a claim of improved
HRQL) because such a claim implies improvement on all
domains that are important to the general concept. Use of
domain subsets as study endpoints presupposes that the
PRO instrument was adequately developed and validated
to measure the subset of domains independently from the
other domains.
The FDA recommends that the sponsor discuss with the
FDA in advance of the study the appropriateness of the
statistical strategies proposed in the SAP.
5.3 Statistical considerations for composite measures
Understanding the usefulness and measurement proper-
ties of a composite endpoint (i.e., an index, profile, or bat-
tery of scores) is an iterative process that evolves over
time. Rules for interpretation of composite measures
depend on substantial clinical experience with the meas-
ure in the clinical trial setting. Development of a compos-
ite endpoint at the time the confirmatory clinical study
protocol is generated is discouraged unless there is sub-
stantial prior empirical evidence of the value of the chosen
components of the composite. Though one reason for use
of a composite is to reduce the multiplicity problems asso-
ciated with multiple separate endpoints, composites can
do so only if it is agreed that treatment impact on each of
the endpoints is of value and if the endpoints move in the
same direction.
Establishing benefit is difficult if only one component of
a composite endpoint responds to the treatment. For
example, a treatment may relieve certain symptoms or
improve functioning but this benefit may not be detected
using a composite score that includes other endpoints
(e.g., psychological or emotional well-being) that fail to
improve with the treatment. In any such composite, it is
critical to ensure that patients enrolled in a clinical study
are impaired in all domains (e.g., psychological or emo-
tional well-being) because they cannot improve in
domains if they are not impaired in whatever concept the
domain measures.
Multiplicity problems arise when the multiple individual
components of a composite endpoint are intended as pos-
sible claims. In general, individual components of a com-
posite measure will not be adequate to support a claim
unless the components are prespecified in the SAP as sep-
arate endpoints, either sharing overall study alpha (co-pri-
mary endpoints) or identified in a sequential analysis,
and the study results are found statistically and clinically
meaningful in the context of the total composite and
other individual component results.
In general, if analysis of scores for the individual compo-
nent endpoints of a composite shows the improvement is
driven primarily by a single domain (e.g., performance of
a specific activity), the findings for the composite score
would not support a general claim (e.g., psychological or
emotional benefit, or even general physical state if all that
is shown is symptom improvement).
5.4 Statistical considerations for patient-level missing data
The FDA recommends that the SAP address plans for how
the statistical analyses will handle missing data when eval-
uating treatment efficacy and when considering patient
success or patient response.
5.4.1 Missing items within domains
At a specific patient visit, a domain measurement may be
missing some, but not all, items. Defining rules that spec-
ify the number of items that can be missing and still con-
sider the domain to have been measured is one approach
to handling this type of missing data. Rules for handling
missing data should be specific to each PRO instrument
and should usually be determined during the instrument
development and validation process. The FDA recom-
mends that all rules be specified in the SAP. For example,
the SAP can specify that a domain will be treated as miss-
ing if more than 25 percent of the items are missing; if less
than 25 percent of the items are missing, the domain score
can be taken to be the average of the nonmissing items.
5.4.2 Missing entire domains or entire measurements
When the amount of missing data becomes large, study
results can be inconclusive. As described earlier, the FDA
encourages prespecified procedures in the study protocol,
particularly when patients discontinue study treatment.
Because missing data may be due to the treatment
received or the underlying disease and can introduce bias
in the analysis of treatment differences and conclusions
about treatment impact, the FDA encourages sponsors to
obtain data on each patient at the time of withdrawal to
determine the reason for withdrawal. When available, this
information can be taken into account in the analysis.
A variety of statistical strategies have been proposed in the
literature and applications to the FDA to deal with missing
data due to patient withdrawal from assigned treatment
exposure prior to planned completion of the trial. No sin-
gle method is generally accepted as preferred. One used in
the past was to exclude subjects from the analyses if they
did not complete the study (i.e., completers' analysis). This
strategy is generally inadvisable because the reason for
missing data can be treatment-related and these patients
may not adequately represent the study population.
Another common, albeit problematic, strategy is to use
the last observation available as the final evaluation – usu-Health and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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ally referred to as last observation carried forward (LOCF).
Even though LOCF enables every patient randomized to
contribute some observation to the analysis, it can be
problematic for the following reasons:
• If the objective of the trial is to detect a treatment effect
after a certain duration of treatment (e.g., at 8 weeks),
then a comparison that includes only measurements on
patients at earlier times or visits is not addressing the orig-
inal trial objective. The average of patient responses, many
of which are at different times or visits, may be uninter-
pretable.
• LOCF makes an implicit assumption that the patient
would sustain the same response seen at an early study
visit for the entire duration of the trial. This assumption is
untestable and potentially unrealistic.
Some other approaches involve imputation of missing
data on a per-patient basis. These strategies try to predict
missing outcomes for a patient who has withdrawn from
the trial using data from subjects who stayed in the trial
and for whom all data have been collected. All of these
strategies are imperfect, as they involve strong or weak
assumptions about what caused data to be missing,
assumptions that usually cannot be verified from the data.
If missing data are associated with treatment effect in ways
that cannot be predicted from measurements on subjects
with complete data, analyses using imputation proce-
dures will be biased. When there are few patients with
missing measurements and the frequency of missing data
or proportion of patients with missing data is comparable
across treatment groups, most approaches will yield simi-
lar results. When a higher proportion of patients have
missing data, the FDA recommends the use of several dif-
ferent imputation methods (including a worst-case sce-
nario in which missing data are assumed to be
unfavorable for those on the investigational treatment
and favorable for those in the control group) and an
assessment of the consistency of the study results using
each method. These analyses will demonstrate the sensi-
tivity of the conclusions to the assumptions made by the
different methods.
5.5 Interpretation of study results
Because statistical significance can sometimes be achieved
for very small changes if a study is large enough, it is
tempting to identify an MID as a benchmark for interpret-
ing the clinical importance or relevance of study results. If
the MID is truly to be the smallest effect considered mean-
ingful, however, it would be logical to establish the null
hypothesis to rule out a difference less than or equal to the
MID. This is rarely done, and would have major implica-
tions for sample size.
When clinical trials show small mean effect sizes, rather
than considering results in terms of an MID, it may be
more informative to examine the distribution of
responses between treatment groups to more fully charac-
terize the treatment effect and examine the possibility that
the mean improvement reflects very different responses in
subsets of patients. When only a modest fraction of peo-
ple respond to a treatment, that fraction may experience
meaningful change in the face of a mean effect that is very
small. When defining a meaningful change on an individ-
ual patient basis (i.e., a responder), that definition is gen-
erally larger than the minimum important difference for
application to group mean comparisons.
Glossary
Claim
A statement of treatment benefit or comparative safety
advantage. A claim can appear in any section of a medical
product's FDA-approved label or in advertising of pre-
scription drugs.
Cognitive debriefing
A qualitative research tool used to determine whether
concepts and items are understood by patients in the same
way that instrument developers intend. Cognitive debrief-
ing interviews involve incorporating follow-up questions
in a field test interview to gain a better understanding of
how patients interpret questions asked of them.
Concept
The specific goal of measurement (i.e., the thing that is to
be measured by a PRO instrument).
Conceptual framework
The expected relationships of items within a domain and
of domains within a PRO concept. The validation process
confirms the conceptual framework. When used in a clin-
ical trial, the observed relationships among items and
domains will again confirm the conceptual framework.
Domain
A domain is a discrete concept within a multidomain con-
cept. All the items in a single domain contribute to the
measurement of the domain concept.
Health-related quality of life (HRQL)
A multidomain concept that represents the patient's over-
all perception of the impact of an illness and its treatment.
An HRQL measure captures, at a minimum, physical, psy-
chological (including emotional and cognitive), and
social functioning. Claiming a statistical and meaningful
improvement in HRQL implies: (1) that the instrument
measures all HRQL domains that are important to inter-
preting change in how the study population feels or func-
tions as a result of treatment; and (2) that improvementHealth and Quality of Life Outcomes 2006, 4:79 http://www.hqlo.com/content/4/1/79
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was demonstrated in all of the important domains. An
HRQL instrument is a particular type of PRO instrument.
Instrument
A means to capture data (e.g., questionnaire, diary) plus
all the information and documentation that supports its
use. Generally, that includes clearly defined methods and
instructions for administration or responding, a standard
format for data collection, and well-documented methods
for scoring, analysis, and interpretation of results.
Item
An individual question, statement, or task that is evalu-
ated by the patient to address a particular concept.
Minimum important difference (MID)
The amount of difference or change observed in a PRO
measure between treatment groups in a clinical trial that
will be interpreted as a treatment benefit.
Patient-reported outcome (PRO)
Any report coming directly from patients (i.e., study sub-
jects) about a health condition and its treatment.
Quality of life
A general concept that implies an evaluation of the impact
of all aspects of life on general well-being. Because this
term implies the evaluation of nonhealth-related aspects
of life, it is too broad to be considered appropriate for a
medical product claim.
Questionnaire
A set of questions or items shown to a respondent in order
to get answers for research purposes.
Scale
The system of numbers or verbal anchors by which a value
or score is derived. Examples include visual analogue
scales, Likert scales, and rating scales.
Score
A number derived from a patient's response to items in a
questionnaire. A score is computed based on a prespeci-
fied, validated scoring algorithm and is subsequently used
in statistical analyses of clinical study results. Scores can
be computed for individual items, domains, or concepts,
or as a summary of items, domains, or concepts.
Treatment benefit
An improvement in how a patient survives, feels, or func-
tions as a result of treatment. Measures that do not directly
capture the impact of treatment on how a patient survives,
feels, or functions are surrogate measures of treatment
benefit.
Validation
The process of assessing a PRO instrument's ability to
measure a specific concept or collection of concepts. This
ability is described in terms of the instrument's measure-
ment properties that are derived during the validation
process. At the conclusion of the process, a set of measure-
ment properties is produced that are specific to the spe-
cific population and the specific form and format of the
PRO instrument tested. The validation process involves:
• Identifying the concept to be measured
• Assessing the content validity (i.e., being sure the items
in the questionnaire cover all important aspects of the
concept from the patient perspective)
• Evaluating the proposed scores to be obtained from the
instrument
• Defining a priori hypotheses of the expected relation-
ships between PRO concepts and other measures
• Testing the hypotheses by reporting the observed corre-
lations among scores
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Appendix
1. Labeling, as used in this guidance, refers to the medical
product description and summary of use, safety, and effec-
tiveness that must be approved by the FDA. See 21 CFR
201.56 and 201.57 for regulations pertaining to prescrip-
tion drug (including biological drug) labeling. For medi-
cal device labeling, see 21 CFR 801. For blood and blood
products for transfusion, see 21 CFR 606.122 Instruction
Circular.
2. For drugs, section 505(d) of the Federal Food, Drug,
and Cosmetic Act (the Act) establishes substantial evidence
as the evidence standard for making conclusions that a
drug will have a claimed effect and states that reports of
adequate and well-controlled investigations provide the
basis for determining whether there is substantial evidence
to support claims of effectiveness for new drugs. See 21
CFR 314.126 for a description of the characteristics of an
adequate and well-controlled investigation. See the guid-
ance for industry Providing Clinical Evidence of Effectiveness
for Human Drug and Biological Products for considerations
concerning the quantity of evidence necessary to meet the
substantial evidence standard http://www.fda.gov/cder/
guidance/index.htm. For medical devices, the Medical
Device Amendments of 1976 to the Act established the
assurance of safety and effectiveness of medical devices
intended for human use. See 21 CFR 860.7 for the evi-
dence used in the determination of safety and effective-
ness of a medical device.
3. The FDA is specifically asking for comment on the need
for, and appropriate standards for, MID definitions
applied to PRO instruments used in clinical studies.
4. The FDA is specifically asking for comment on the
appropriate review standards for the definition of a
responder when applied to PRO instruments used in clin-
ical studies to support medical product development.
5. For the principal record keeping requirements for clini-
cal investigators and sponsors, see 21 CFR 312.50, 312.58,
312.62, 312.68, 812.140, and 812.145.
6. See the draft guidance for industry Computerized Systems
Used in Clinical Trials. When final, this guidance will
supersede the guidance of the same name issued in April
1999 and will represent the FDA's current thinking on this
topic. For the most recent version of a guidance, check the
CDER guidance Web page at http://www.fda.gov/cder/
guidance/index.htm.
7. See the guidance for industry Part 11, Electronic Records;
Electronic Signatures – Scope and Application http://
www.fda.gov/cder/guidance/index.htm
8. The FDA specifically welcomes comment and addi-
tional information that will inform these policies as new
electronic PRO technology is developed and used in the
medical product development setting.
9. See the ICH guidance for industry E9 Statistical Princi-
ples for Clinical Trials http://www.fda.gov/cder/guidance/
index.htm
Disclaimer
This draft guidance, when finalized, will represent the
Food and Drug Administration's (FDA's) current thinking
on this topic. It does not create or confer any rights for or
on any person and does not operate to bind FDA or the
public. You can use an alternative approach if the
approach satisfies the requirements of the applicable stat-
utes and regulations. If you want to discuss an alternative
approach, contact the FDA staff responsible for imple-
menting this guidance. If you cannot identify the appro-
priate FDA staff, call the appropriate number listed on the
title page of this guidance.
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